Ecopipam

Drug Profile

Ecopipam

Alternative Names: Ecopipam HCl; PSYRX 101; SCH-39166

Latest Information Update: 28 Sep 2016

Price : $50

At a glance

  • Originator Schering-Plough
  • Developer Psyadon Pharmaceuticals; Schering-Plough; University of California Riverside School of Medicine
  • Class Antipsychotics; Benzazepines; Small molecules
  • Mechanism of Action Dopamine D1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lesch-Nyhan syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Lesch-Nyhan syndrome
  • Phase II Gilles de la Tourette's syndrome
  • Preclinical Speech disorders
  • No development reported Gambling
  • Discontinued Cocaine abuse; Obesity; Schizophrenia

Most Recent Events

  • 20 Sep 2016 Preclinical trials in Speech disorders in USA before September 2016 (PO)
  • 20 Sep 2016 University of California plans a phase II/III trial for Speech disorder in USA (NCT02909088)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Lesch-Nyhan-syndrome(In volunteers) in USA (PO, Controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top